Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386947987> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W4386947987 endingPage "S171" @default.
- W4386947987 startingPage "S170" @default.
- W4386947987 abstract "Aldesleukin, recombinant human IL-2 (rIL-2), has been approved by the FDA for the treatment of melanoma and renal cancer. However, effective cytokine therapy is limited by its short half-life in circulation and the severe adverse effects associated with high systemic exposure when administered IV. Edwards et al. studied IP administration of rIL-2 in platinum-resistant and platinum-refractory ovarian cancer (n = 24) with an ORR of 25% (4 complete, 2 partial responses). However, the use of an in-dwelling peritoneal catheter led to a significant number of patients having catheter obstruction, infection, or infusion pain. To overcome these limitations, Avenge Bio has developed a localized cytokine delivery platform - LOCOcyte™ - comprised of polymer-encapsulated epithelial cells that produce potent immune effector molecules for locoregional delivery with temporal regulation. AVB-001 is engineered to produce native IL-2 for the treatment of ovarian cancer." @default.
- W4386947987 created "2023-09-23" @default.
- W4386947987 creator A5000158770 @default.
- W4386947987 creator A5013597759 @default.
- W4386947987 creator A5015116006 @default.
- W4386947987 creator A5031112242 @default.
- W4386947987 creator A5031954051 @default.
- W4386947987 creator A5036201261 @default.
- W4386947987 creator A5037092119 @default.
- W4386947987 creator A5043136359 @default.
- W4386947987 creator A5043978165 @default.
- W4386947987 creator A5044801580 @default.
- W4386947987 creator A5052266561 @default.
- W4386947987 creator A5066488972 @default.
- W4386947987 creator A5067917508 @default.
- W4386947987 creator A5069968605 @default.
- W4386947987 creator A5071360122 @default.
- W4386947987 creator A5083399124 @default.
- W4386947987 date "2023-09-01" @default.
- W4386947987 modified "2023-10-03" @default.
- W4386947987 title "Favorable preclinical efficacy and safety profile of AVB-001, a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first-in-human clinical development (1271)" @default.
- W4386947987 doi "https://doi.org/10.1016/j.ygyno.2023.06.178" @default.
- W4386947987 hasPublicationYear "2023" @default.
- W4386947987 type Work @default.
- W4386947987 citedByCount "0" @default.
- W4386947987 crossrefType "journal-article" @default.
- W4386947987 hasAuthorship W4386947987A5000158770 @default.
- W4386947987 hasAuthorship W4386947987A5013597759 @default.
- W4386947987 hasAuthorship W4386947987A5015116006 @default.
- W4386947987 hasAuthorship W4386947987A5031112242 @default.
- W4386947987 hasAuthorship W4386947987A5031954051 @default.
- W4386947987 hasAuthorship W4386947987A5036201261 @default.
- W4386947987 hasAuthorship W4386947987A5037092119 @default.
- W4386947987 hasAuthorship W4386947987A5043136359 @default.
- W4386947987 hasAuthorship W4386947987A5043978165 @default.
- W4386947987 hasAuthorship W4386947987A5044801580 @default.
- W4386947987 hasAuthorship W4386947987A5052266561 @default.
- W4386947987 hasAuthorship W4386947987A5066488972 @default.
- W4386947987 hasAuthorship W4386947987A5067917508 @default.
- W4386947987 hasAuthorship W4386947987A5069968605 @default.
- W4386947987 hasAuthorship W4386947987A5071360122 @default.
- W4386947987 hasAuthorship W4386947987A5083399124 @default.
- W4386947987 hasConcept C121608353 @default.
- W4386947987 hasConcept C126322002 @default.
- W4386947987 hasConcept C143998085 @default.
- W4386947987 hasConcept C197934379 @default.
- W4386947987 hasConcept C203014093 @default.
- W4386947987 hasConcept C2777701055 @default.
- W4386947987 hasConcept C2778690821 @default.
- W4386947987 hasConcept C2780427987 @default.
- W4386947987 hasConcept C2780674031 @default.
- W4386947987 hasConcept C71924100 @default.
- W4386947987 hasConcept C8891405 @default.
- W4386947987 hasConceptScore W4386947987C121608353 @default.
- W4386947987 hasConceptScore W4386947987C126322002 @default.
- W4386947987 hasConceptScore W4386947987C143998085 @default.
- W4386947987 hasConceptScore W4386947987C197934379 @default.
- W4386947987 hasConceptScore W4386947987C203014093 @default.
- W4386947987 hasConceptScore W4386947987C2777701055 @default.
- W4386947987 hasConceptScore W4386947987C2778690821 @default.
- W4386947987 hasConceptScore W4386947987C2780427987 @default.
- W4386947987 hasConceptScore W4386947987C2780674031 @default.
- W4386947987 hasConceptScore W4386947987C71924100 @default.
- W4386947987 hasConceptScore W4386947987C8891405 @default.
- W4386947987 hasLocation W43869479871 @default.
- W4386947987 hasOpenAccess W4386947987 @default.
- W4386947987 hasPrimaryLocation W43869479871 @default.
- W4386947987 hasRelatedWork W157270364 @default.
- W4386947987 hasRelatedWork W2030612376 @default.
- W4386947987 hasRelatedWork W2047209980 @default.
- W4386947987 hasRelatedWork W2107710620 @default.
- W4386947987 hasRelatedWork W2793246083 @default.
- W4386947987 hasRelatedWork W2864532522 @default.
- W4386947987 hasRelatedWork W3032907499 @default.
- W4386947987 hasRelatedWork W3136661288 @default.
- W4386947987 hasRelatedWork W4360983034 @default.
- W4386947987 hasRelatedWork W2396811992 @default.
- W4386947987 hasVolume "176" @default.
- W4386947987 isParatext "false" @default.
- W4386947987 isRetracted "false" @default.
- W4386947987 workType "article" @default.